Abeona Therapeutics Inc.
ABEO
$4.95
$0.275.77%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -100.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -100.00% |
| Cost of Revenue | 9.74% | 31.44% | -87.51% | -10.37% | 376.27% |
| Gross Profit | -9.74% | -31.44% | -113.12% | 10.37% | -381.41% |
| SG&A Expenses | 31.70% | 54.09% | 72.20% | 78.21% | 2.60% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 26.22% | 35.39% | 18.16% | 19.04% | 9.58% |
| Operating Income | -26.22% | -35.39% | -53.75% | -19.04% | -10.20% |
| Income Before Tax | 43.99% | -155.74% | 144.47% | -246.74% | -132.99% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 43.99% | -155.74% | 144.47% | -246.74% | -132.99% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 43.99% | -155.74% | 144.47% | -246.74% | -132.99% |
| EBIT | -26.22% | -35.39% | -53.75% | -19.04% | -10.20% |
| EBITDA | -26.85% | -37.41% | -57.92% | -21.64% | -12.98% |
| EPS Basic | 70.44% | -31.89% | 120.03% | -114.59% | -21.65% |
| Normalized Basic EPS | 70.35% | -31.91% | 118.83% | -114.58% | -43.20% |
| EPS Diluted | 70.44% | -31.89% | 71.60% | -114.59% | -21.65% |
| Normalized Diluted EPS | 70.35% | -31.91% | 114.71% | -114.58% | -43.20% |
| Average Basic Shares Outstanding | 89.46% | 93.90% | 122.06% | 61.59% | 91.51% |
| Average Diluted Shares Outstanding | 89.46% | 93.90% | 184.31% | 61.59% | 91.51% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
